// App-Quantinova.ai

SAT0397 : GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED

Researchers

Presenter

  • C. T. Ritchlin

Principal Investigators

  • P. Helliwell

  • W. H. Boehncke

  • E. C. Hsia

  • A. Kollmeier

  • R. A. Subramanian

  • X. L. Xu

  • S. Sheng

  • Y. Jiang

  • B. Zhou

  • A. Deodhar

Medical Centers

  • U Rochester Med Ctr, Rochester, United States of America

  • U Leeds, Leeds, United Kingdom

  • Geneva University Hospitals, Geneva, Switzerland

  • Janssen Research & Development, Raritan, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

  • Oregon Health & Science Univ, Portland, United States

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • C reactive protein

  • Interleukin-23

  • Albumin/creatinine

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • UCB Pharma

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved